Coprescribing of opioids and psychotropic medications among Medicare-enrolled older adults on long-term opioid therapy

J Am Pharm Assoc (2003). 2023 Nov-Dec;63(6):1753-1760.e5. doi: 10.1016/j.japh.2023.08.019. Epub 2023 Aug 24.

Abstract

Background: Pressures to reduce opioid prescribing have potential to incentivize coprescribing of opioids (at lower dose) with psychotropic medications. Evidence concerning the extent of the problem is lacking. This study assessed trends in coprescribing and characterized coprescribing patterns among Medicare-enrolled older adults with chronic noncancer pain (CNCP) receiving long-term opioid therapy (LTOT).

Methods: A cohort study was conducted using 2012-2018 5% National Medicare claims data. Eligible beneficiaries were continuously enrolled and had no claims for cancer diagnoses or hospice use, and ≥ 2 claims with diagnoses for CNCP conditions within a 30-day period in the 12 months before the index date (LTOT initiation). Coprescribing was defined as an overlap between opioids and any class of psychotropic medication (antidepressants, benzodiazepines, antipsychotics, anticonvulsants, muscle relaxants, and nonbenzodiazepine hypnotics) based on their prescription fill dates and days of supply in a given year. The occurrence of coprescribing, coprescribing intensity, and number of days of overlap with psychotropic medications were calculated for each calendar year.

Results: The eligible study population of individuals on LTOT ranged from 2038 in 2013 to 1751 in 2018. The occurrence of coprescribing among eligible beneficiaries decreased from 73.41% in 2013 to 70.81% in 2015 and then increased slightly to 71.22% in 2018. Among eligible beneficiaries with at least one overlap day, the coprescribing intensity with any class of psychotropic medications showed minimal variation throughout the study period: 74.73% in 2013 and 72.67% in 2018. Across all the years, the coprescribing intensity was found to be highest with antidepressants (2013, 49.90%; 2018, 50.33%) followed by benzodiazepines (2013, 25.42%; 2018, 19.95%).

Conclusion: Coprescribing was common among older adults with CNCP who initiated LTOT but did not rise substantially in the period studied. Future research should investigate drivers behind coprescribing and safety of various patterns of use.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Analgesics, Opioid* / therapeutic use
  • Antidepressive Agents / therapeutic use
  • Benzodiazepines / therapeutic use
  • Chronic Pain* / drug therapy
  • Cohort Studies
  • Humans
  • Medicare
  • Practice Patterns, Physicians'
  • Psychotropic Drugs / therapeutic use
  • Retrospective Studies
  • United States

Substances

  • Analgesics, Opioid
  • Psychotropic Drugs
  • Benzodiazepines
  • Antidepressive Agents